Filter by: patients
Home > Community Treatment Reports and Side Effects > Gelnique Treatment Report
What is Gelnique?

Gelnique™ is a brand name for oxybutynin chloride in a 10% gel preparation. It is used to reduce the symptoms of overactive bladder, including frequency and urgency of urination.

Reported Purpose & Efficacy

Reasons and Efficacy
Purpose # of patients
# of patients with evaluations Efficacy
Major
Moderate
Slight
None
Can’t tell
Urinary urgency 4 2 Efficacy_moderate Efficacy_none
Overactive bladder, neurogenic bladder, urgency. 3 2 Efficacy_major Efficacy_moderate
Urinary Incontinence 1 0
Bladder problems 1 1 Efficacy_major

See all 7 patients currently taking Gelnique

Mouse over the table for more information

Reported Side Effects

Side effects as an overall problem

Severe
 0
Moderate
 0
Mild
 1
None
 4

Reported Dosages

  10% as needed 10 g daily
  1 Number of Patients: 1 6 Number of Patients: 6  

Reported Stop Reasons

Why Patients Stopped Taking Gelnique (multiple reasons could be selected)
Reason # Patients Percentage of patients
Other 2   Other: 67%
Did not seem to work 1   Did not seem to work: 33%
Course of treatment ended 1   Course of treatment ended: 33%

See all 3 patients who’ve stopped taking Gelnique

Reported Duration See details about how long patients take this treatment ▼

Currently Taking Gelnique

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0

Stopped Taking Gelnique

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0

Reported Adherence, Burden & Cost See details from patient evaluations ▼

Adherence

Taking treatment as prescribed

Adherence of Gelnique

Always
 2 40%
Usually
 2 40%
Sometimes
 0 0%
Never
 1 20%

Burden

Difficulty being on treatment

Burden of Gelnique

Very
 0 0%
Somewhat
 0 0%
A little
 1 20%
Not at all
 4 80%

Cost

Paid out of pocket

Cost of Gelnique

$200+
 0 0%
$100-199
 0 0%
$50-99
 1 33%
$25-49
 0 0%
< $25
 2 67%

See more information, including instructions, precautions, side effects, and interactions.

Report created on May 25, 2012.